Literature DB >> 18957817

Effects of decreased renal cortical expression of G protein-coupled receptor kinase 4 and angiotensin type 1 receptors in rats.

Junichi Yatabe1, Hironobu Sanada, Sanae Midorikawa, Shigeatsu Hashimoto, Tsuyoshi Watanabe, Peter M Andrews, Ines Armando, Xiaoyan Wang, Robin A Felder, Pedro A Jose.   

Abstract

Abnormalities in renal angiotensin type 1 receptor (AT1R), D1 dopamine receptor (D1R) and G protein-coupled receptor kinase 4 (GRK4) are present in polygenic hypertension. Selective renal reduction of AT1R expression by intrarenal cortical infusion of antisense oligodeoxynucleotides (As-Odns) in conscious, uninephrectomized, sodium-loaded rats decreases proteinuria, normalizes the glomerular sclerosis index (GSI), increases the sodium excretion (UNaV), and modestly increases blood pressure (BP) in spontaneously hypertensive rats (SHR) but not in normotensive Wistar-Kyoto rats (WKY). In contrast, selective renal reduction of GRK4 expression by infusion of GRK4 As-Odns increases UnaV, attenuates the increase in arterial BP with age, and modestly decreases protein excretion in SHR, but not in WKY. In this study, we report that intrarenal cortical infusion of both GRK4 and AT1R As-Odns decreased BP and increased UNaV in SHR; these effects were also noted in WKY to a lesser extent. Infusion of SHR with this combination of As-Odns resulted in a decrease in proteinuria and improvement of GSI similar to those by AT1R As-Odn only. In contrast to the increased circulating angiotensin II and aldosterone levels induced by AT1R As-Odn alone, the combination of As-Odns decreased both, contributing to greater natriuresis and amelioration of hypertension than by GRK4 or AT1R As-Odn only. Our results indicate an interaction between GRK4-regulated receptors and the renin-angiotensin system in the regulation of renal function and BP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18957817      PMCID: PMC3731072          DOI: 10.1291/hypres.31.1455

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  40 in total

Review 1.  Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system.

Authors:  Julie L Lavoie; Curt D Sigmund
Journal:  Endocrinology       Date:  2003-06       Impact factor: 4.736

Review 2.  Regulation of intrarenal angiotensin II in hypertension.

Authors:  L Gabriel Navar; Lisa M Harrison-Bernard; Akira Nishiyama; Hiroyuki Kobori
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

3.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  G protein-coupled receptor kinase 4 gene variants in human essential hypertension.

Authors:  Robin A Felder; Hironobu Sanada; Jing Xu; Pei-Ying Yu; Zheng Wang; Hidetsuna Watanabe; Laureano D Asico; Wei Wang; Shaopeng Zheng; Ikuyo Yamaguchi; Scott M Williams; James Gainer; Nancy J Brown; Debra Hazen-Martin; Lee-Jun C Wong; Jean E Robillard; Robert M Carey; Gilbert M Eisner; Pedro A Jose
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

5.  Dopamine D(3) receptors and salt-dependent hypertension.

Authors:  Gerd Luippold; Claudia Zimmermann; Matthias Mai; Doris Kloor; Dorothea Starck; Gerhard Gross; Bernd Mühlbauer
Journal:  J Am Soc Nephrol       Date:  2001-11       Impact factor: 10.121

Review 6.  Sympathetic nervous system and the kidney in hypertension.

Authors:  Gerald F DiBona
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-03       Impact factor: 2.894

7.  Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans.

Authors:  M Haney; A S Ward; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

8.  Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: insights into mechanism.

Authors:  J Panos; M F Michelis; M V DeVita; R H Lavie; B M Wilkes
Journal:  Clin Nephrol       Date:  2003-07       Impact factor: 0.975

Review 9.  Renal dopamine receptors and hypertension.

Authors:  Tahir Hussain; Mustafa F Lokhandwala
Journal:  Exp Biol Med (Maywood)       Date:  2003-02

10.  Role of G protein-coupled receptor kinase 4 and beta-arrestin 1 in agonist-stimulated metabotropic glutamate receptor 1 internalization and activation of mitogen-activated protein kinases.

Authors:  Luisa Iacovelli; Lorena Salvatore; Loredana Capobianco; Antonietta Picascia; Eliana Barletta; Marianna Storto; Stefania Mariggiò; Michele Sallese; Antonio Porcellini; Ferdinando Nicoletti; Antonio De Blasi
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

View more
  10 in total

Review 1.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs.

Authors:  Eugenia V Gurevich; John J G Tesmer; Arcady Mushegian; Vsevolod V Gurevich
Journal:  Pharmacol Ther       Date:  2011-08-26       Impact factor: 12.310

2.  Increased renal oxidative stress in salt-sensitive human GRK4γ486V transgenic mice.

Authors:  Zhenyu Diao; Laureano D Asico; Van Anthony M Villar; Xiaoxu Zheng; Santiago Cuevas; Ines Armando; Pedro A Jose; Xiaoyan Wang
Journal:  Free Radic Biol Med       Date:  2017-02-09       Impact factor: 7.376

Review 3.  The Role of Aldosterone in Obesity-Related Hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Am J Hypertens       Date:  2016-02-28       Impact factor: 2.689

4.  Role of GRK4 in the regulation of the renal ETB receptor in hypertension.

Authors:  Yang Yang; Meixiang Li; Xue Zou; Caiyu Chen; Shuo Zheng; Chunjiang Fu; Ken Chen; Pedro A Jose; Cong Lan; Yukai Liu
Journal:  FASEB J       Date:  2020-07-20       Impact factor: 5.191

5.  Common variants of the G protein-coupled receptor type 4 are associated with human essential hypertension and predict the blood pressure response to angiotensin receptor blockade.

Authors:  H Sanada; M Yoneda; J Yatabe; S M Williams; J Bartlett; M J White; L N Gordon; R A Felder; G M Eisner; I Armando; P A Jose
Journal:  Pharmacogenomics J       Date:  2015-03-03       Impact factor: 3.550

6.  Effects of renal Na+/Ca2+ exchanger 1 inhibitor (SEA0400) treatment on electrolytes, renal function and hemodynamics in rats.

Authors:  Midori Sasaki Yatabe; Junichi Yatabe; Kozue Takano; Hironobu Sanada; Junko Kimura; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2014-11-20       Impact factor: 2.801

7.  Role of GRK4 in the regulation of arterial AT1 receptor in hypertension.

Authors:  Ken Chen; Chunjiang Fu; Caiyu Chen; Li Liu; Hongmei Ren; Yu Han; Jian Yang; Duofen He; Lin Zhou; Zhiwei Yang; Lianfeng Zhang; Pedro A Jose; Chunyu Zeng
Journal:  Hypertension       Date:  2013-11-11       Impact factor: 10.190

8.  A novel role for c-Myc in G protein-coupled receptor kinase 4 (GRK4) transcriptional regulation in human kidney proximal tubule cells.

Authors:  John J Gildea; Hanh T Tran; Robert E Van Sciver; Dora Bigler Wang; Julia M Carlson; Robin A Felder
Journal:  Hypertension       Date:  2013-03-18       Impact factor: 10.190

9.  Human GRK4γ142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition.

Authors:  Zheng Wang; Chunyu Zeng; Van Anthony M Villar; Shi-You Chen; Prasad Konkalmatt; Xiaoyan Wang; Laureano D Asico; John E Jones; Yu Yang; Hironobu Sanada; Robin A Felder; Gilbert M Eisner; Matthew R Weir; Ines Armando; Pedro A Jose
Journal:  Hypertension       Date:  2015-12-14       Impact factor: 10.190

10.  Novel role of sorting nexin 5 in renal D(1) dopamine receptor trafficking and function: implications for hypertension.

Authors:  Van Anthony M Villar; Ines Armando; Hironobu Sanada; Lauren C Frazer; Christen M Russo; Patricia M Notario; Hewang Lee; Lauren Comisky; Holly Ann Russell; Yu Yang; Julie A Jurgens; Pedro A Jose; John E Jones
Journal:  FASEB J       Date:  2012-11-29       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.